BioLineRx has filed a 20-F – Annual and transition report of foreign private issuers [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 20-F, BioLineRx, MAR 23, 2015, View Source [SID1234502466]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BioLineRx has filed a 20-F/A [Amend] – Annual and transition report of foreign private issuers [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, BioLineRx, MAR 23, 2015, View Source [SID1234502488]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

IDD001 MAb exhibited the highest Complement Dependent Cytotoxicity (CDC) efficiency on B-ALL sample

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

From its proprietary MAb library, iDD biotech has generated:
· next-generation, humanized, Fc optimized and afucosylated anti CD19 MAb,
· with higher level of apoptosis compared with MAbs anti CD19 under development,
· with enhanced binding of Fc
RIIIa and ADCC (patent WO/2012/010561/01056),
· against a broad range of B-lymphoma and leukaemia cell lines,
· with or without complement binding ability (MAb IDD001 versus MAb IDD002),
· produced using generic wild type CHO cell lines.

(Poster, iDD biotech, View Source [SID:1234502457])

Both IDD001 and ID002 exhibited antitumor efficacy and induced inhibition of tumor growth in vivo, demonstrating that CD19 is an attractive alternative target to circumvent Rituximab resistance for B-CLL treatment (Poster, iDD biotech, Circumventing Rituximab resistance for B-CLL treatment by using anti CD19 MAb, View Source [SID:1234502458]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

IBI305 is a biosimilar version of bevacizumab which is under development by Innovent Biologics for the treatment of colorectal cancer, lung cancer and other malignancies (Company Pipeline, Innovent Biologics, MAR 20, 2015, View Source;type=IBI305 [SID:1234502442]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!